NCT06159491View on ClinicalTrials.gov

Pacritinib in CMML

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 18, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Chronic Myelomonocytic Leukemia
Interventions
DRUG

Pacritinib

Participants will take Pacritinib 100 mg - 200mg BID for each 28 day cycle

DRUG

Azacitidine

Azacitidine 75mg/m\^2 will be administered IV or SQ QD D1-7 of each 28 day cycle

Trial Locations (1)

10029

RECRUITING

The Mount Sinai Hospital, New York

All Listed Sponsors
collaborator

Sobi, Inc.

INDUSTRY

lead

Douglas Tremblay

OTHER